Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers
Treatment of recurrent oligometastatic gynecologic malignancy may involve targeted surgery, thermal ablation, or CT-guided high-dose-rate interstitial brachytherapy ablation (CT-HDR-IBTA). The purpose of this study was to describe the safety and efficacy of CT-HDR-IBTA for oligometastatic gynecologic malignancies. (Source: Brachytherapy)
Source: Brachytherapy - March 6, 2024 Category: Cancer & Oncology Authors: Tiffany S. Lai, Alex Francoeur, Erica Manrriquez, Puja Venkat, Albert Chang, Michael Douek, Simin Bahrami, Steven S. Raman, Sanaz Memarzadeh Source Type: research
Editorial Board
(Source: Brachytherapy)
Source: Brachytherapy - March 1, 2024 Category: Cancer & Oncology Source Type: research
Masthead
(Source: Brachytherapy)
Source: Brachytherapy - March 1, 2024 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Brachytherapy)
Source: Brachytherapy - March 1, 2024 Category: Cancer & Oncology Source Type: research
Focal brachytherapy as definitive treatment for localized prostate cancer: A systematic review and meta-analysis
In this systematic review and meta-analysis, we describe the oncologic and toxicity outcomes of definitive focal brachytherapy for prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - March 1, 2024 Category: Cancer & Oncology Authors: Osama Mohamad, Luca Nicosia, Etienne Mathier, Elena Riggenbach, Constantinos Zamboglou, Daniel M. Aebersold, Fillipo Alongi, Mohamed Shelan Tags: Original Article Source Type: research
Time-action and patient experience analyses of locally advanced cervical cancer brachytherapy
Although MRI-based image guided adaptive brachytherapy (IGABT) for locally advanced cervical cancer (LACC) has resulted in favorable outcomes, it can be logistically complex and time consuming compared to 2D image-based brachytherapy, and both physically and emotionally intensive for patients. This prospective study aims to perform time-action and patient experience analyses during IGABT to guide further improvements. (Source: Brachytherapy)
Source: Brachytherapy - February 27, 2024 Category: Cancer & Oncology Authors: Sharline M. van Vliet –Pérez, Rosemarijn van Paassen, Linda S.G.L. Wauben, Robin Straathof, Nick J. van de Berg, Jenny Dankelman, Ben J.M. Heijmen, Inger–Karine K. Kolkman–Deurloo, Remi A. Nout Tags: Original Article Source Type: research
Design approach and benefits of the 3D-printed vaginal individualized applicator (VIA)
Interstitial gynecologic brachytherapy necessitates precise needle placement, requiring time and expertise. We aimed to simplify interstitial procedures and facilitate optimal needle distribution with individualized vaginal templates to guide interstitial needles. (Source: Brachytherapy)
Source: Brachytherapy - February 23, 2024 Category: Cancer & Oncology Authors: Agnes Ewongwo, Thomas Niedermayr, Elizabeth A. Kidd Tags: Original Article Source Type: research
Clinical outcomes in borderline and locally advanced pancreatic cancer with the addition of low-dose-rate brachytherapy to standard of care therapy
Surgical resection remains the only curative therapy for pancreatic cancer. Unfortunately, many patients have borderline or unresectable disease at diagnosis due to proximity of major abdominal vessels. Neoadjuvant chemotherapy and radiation are used to down-stage, however, there is a risk that there will be a positive/close surgical margin. The CivaSheet is a low-dose-rate (LDR) brachytherapy device placed at the time of surgery to target the area of highest risk of margin positivity. The purpose of this study is to assess the clinical value of brachytherapy in addition to standard-of-care therapy in pancreatic therapy. (...
Source: Brachytherapy - February 23, 2024 Category: Cancer & Oncology Authors: Ross J. Taylor, Gregory J. Matthews, Robert H. Aseltine, Emma C. Fields Source Type: research
The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy
Delays in initiating and completing brachytherapy may have adverse oncologic outcomes for patients with cervical, uterine, and prostate cancer. The impact of the COVID-19 pandemic on brachytherapy in the United States has not been well-characterized. (Source: Brachytherapy)
Source: Brachytherapy - February 22, 2024 Category: Cancer & Oncology Authors: Eric Roach, Ryan Hutten, Skyler Johnson, Gita Suneja, Jonathan Tward, Daniel Petereit, David Gaffney Tags: Original Article Source Type: research
Salvage brachytherapy for second ipsilateral breast tumor event: Relating dosimetric analysis to late side effects
This study investigates the impact of APBrI technique and multicatheter interstitial high dose-rate brachytherapy (MIB) dosimetry parameters on toxicity and survival in patients with 2ndIBTE. (Source: Brachytherapy)
Source: Brachytherapy - February 20, 2024 Category: Cancer & Oncology Authors: Mohamed Abdul-Latih, Jocelyn Gal, Renaud Schiappa, Yassine Rizzi, Mathieu Gautier, Jean-Michel Hannoun-Levi Tags: Original Article Source Type: research
A practical method of estimating medium-heterogeneity corrected dose without a Monte Carlo calculation in ocular brachytherapy using 125I COMS plaques
To provide a practical method of estimating medium-heterogeneity corrected dose without a Monte Carlo (MC) calculation in ocular brachytherapy using 125I Collaborative Ocular Melanoma Study (COMS) plaques. (Source: Brachytherapy)
Source: Brachytherapy - February 8, 2024 Category: Cancer & Oncology Authors: Yongsook C. Lee, Mehran Nik Akhtar, Yongbok Kim, Jae Won Jung Tags: Original Article Source Type: research
Patterns of practice survey for cervical cancer brachytherapy in Morocco
This study surveyed radiation oncologists in Morocco to explore current practices and perspectives on brachytherapy for cervix cancer. (Source: Brachytherapy)
Source: Brachytherapy - February 3, 2024 Category: Cancer & Oncology Authors: Tarik Chekrine, Fatima Zahra Bellefkih, Ghita Hatim, Zineb Bouchbika, Nadia Benchakroun, Hassan Jouhadi, Nezha Tawfiq, Souha Sahraoui Tags: Original Article Source Type: research
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review
To assess the impact of the COVID-19 pandemic on the use of brachytherapy in patients with gynecologic and prostate cancers including treatment delays, increased burden of mortality, and associated clinical outcomes. (Source: Brachytherapy)
Source: Brachytherapy - February 1, 2024 Category: Cancer & Oncology Authors: Shreel Parikh, Yingting Zhang, Zohaib Sherwani, Ritesh Kumar, Nisha Ohri, Imraan Jan, Irina Vergalasova, Salma Jabbour, Lara Hathout Tags: Original Article Source Type: research
Keeping your best options open with AI-based treatment planning in prostate and cervix brachytherapy
Without a clear definition of an optimal treatment plan, no optimization model can be perfect. Therefore, instead of automatically finding a single “optimal” plan, finding multiple, yet different near-optimal plans, can be an insightful approach to support radiation oncologists in finding the plan they are looking for. (Source: Brachytherapy)
Source: Brachytherapy - January 31, 2024 Category: Cancer & Oncology Authors: Leah R.M. Dickhoff, Renzo J. Scholman, Danique L.J. Barten, Ellen M. Kerkhof, Jelmen J. Roorda, Laura A. Velema, Lukas J.A. Stalpers, Bradley R. Pieters, Peter A.N. Bosman, Tanja Alderliesten Source Type: research
Establishing a fingerprinting method for fast catheter identification in HDR brachytherapy in vivo dosimetry
To use quantities measurable during in vivo dosimetry to build unique channel identifiers, that enable detection of brachytherapy errors. (Source: Brachytherapy)
Source: Brachytherapy - January 27, 2024 Category: Cancer & Oncology Authors: Daline Tho, C édric Bélanger, Erik B. Jørgensen, Jérémie Tanguay, Haydee M.L. Rosales, Sam Beddar, Jacob G. Johansen, Gustavo Kertzscher, Marie-Claude Lavallée, Luc Beaulieu Tags: Technical Note Source Type: research
